Raymond John Playford

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7772533/raymond-john-playford-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 135
 7,175
 46
 83

 papers
 citations
 h-index
 g-index

 142
 7,774
 11.4
 5.48

 ext. papers
 ext. citations
 avg, IF
 L-index

#	Paper	IF	Citations
135	Effects of Bovine Colostrum with or without Egg on In Vitro Bacterial-Induced Intestinal Damage with Relevance for SIBO and Infectious Diarrhea. <i>Nutrients</i> , 2021 , 13,	6.7	2
134	Oral zinc carnosine reduces multi-organ damage caused by gut ischemia/reperfusion in mice. <i>Journal of Functional Foods</i> , 2021 , 78, 104361	5.1	1
133	Methods to improve efficacy of orally administered bioactive peptides using bovine colostrum as an exemplar. <i>PLoS ONE</i> , 2021 , 16, e0253422	3.7	1
132	Protease Inhibitors Protect Bovine Colostrum or Chicken Egg Growth Factors from Pancreatic Enzyme Digestion in AGS Cells or Colitic Rats. <i>Journal of Nutrition</i> , 2021 , 151, 3036-3044	4.1	1
131	Bovine Colostrum: Its Constituents and Uses. <i>Nutrients</i> , 2021 , 13,	6.7	26
130	Marked variability in bioactivity between commercially available bovine colostrum for human use; implications for clinical trials. <i>PLoS ONE</i> , 2020 , 15, e0234719	3.7	10
129	Review: Insulin resistance and mitochondrial dysfunction following severe burn injury. <i>Peptides</i> , 2020 , 126, 170269	3.8	4
128	Pasteurized Chicken Egg Powder Stimulates Proliferation and Migration of AGS, RIE1, and Caco-2 Cells and Reduces NSAID-Induced Injury in Mice and Colitis in Rats. <i>Journal of Nutrition</i> , 2020 , 150, 1434	- 1 442	10
127	Pancreatic secretory trypsin inhibitor reduces multi-organ injury caused by gut ischemia/reperfusion in mice. <i>PLoS ONE</i> , 2020 , 15, e0227059	3.7	2
126	Oral bovine colostrum supplementation does not increase circulating insulin-like growth factor-1 concentration in healthy adults: results from short- and long-term administration studies. <i>European Journal of Nutrition</i> , 2020 , 59, 1473-1479	5.2	9
125	TAME trial: a multi-arm phase II randomised trial of four novel interventions for malnutrition enteropathy in Zambia and Zimbabwe - a study protocol. <i>BMJ Open</i> , 2019 , 9, e027548	3	4
124	Trefoil factor family peptides enhance cell migration by increasing cellular osmotic permeability and aquaporin 3 levels. <i>FASEB Journal</i> , 2018 , 32, 1017-1024	0.9	6
123	Specific protein supplementation using soya, casein or whey differentially affects regional gut growth and luminal growth factor bioactivity in rats; implications for the treatment of gut injury and stimulating repair. <i>Food and Function</i> , 2018 , 9, 227-233	6.1	1
122	Intestinal fatty acid-binding protein and gut permeability responses to exercise. <i>European Journal of Applied Physiology</i> , 2017 , 117, 931-941	3.4	38
121	Zinc carnosine works with bovine colostrum in truncating heavy exercise-induced increase in gut permeability in healthy volunteers. <i>American Journal of Clinical Nutrition</i> , 2016 , 104, 526-36	7	40
120	Pancreatic secretory trypsin inhibitor causes autocrine-mediated migration and invasion in bladder cancer and phosphorylates the EGF receptor, Akt2 and Akt3, and ERK1 and ERK2. <i>American Journal of Physiology - Renal Physiology</i> , 2013 , 305, F382-9	4.3	17
119	Use of the alpha glucosidase inhibitor acarbose in patients with 'Middleton syndrome': normal gastric anatomy but with accelerated gastric emptying causing postprandial reactive hypoglycemia and diarrhea. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013 , 27, 403-4		21

(2006-2012)

118	IL-1Istimulation of CCD-18co myofibroblasts enhances repair of epithelial monolayers through Wnt-5a. <i>American Journal of Physiology - Renal Physiology</i> , 2012 , 303, G1270-8	5.1	7
117	Dimethyloxalyglycine stimulates the early stages of gastrointestinal repair processes through VEGF-dependent mechanisms. <i>Laboratory Investigation</i> , 2011 , 91, 1684-94	5.9	17
116	Reparative properties of the traditional Chinese medicine Cordyceps sinensis (Chinese caterpillar mushroom) using HT29 cell culture and rat gastric damage models of injury. <i>British Journal of Nutrition</i> , 2011 , 105, 1303-10	3.6	18
115	The nutriceutical bovine colostrum truncates the increase in gut permeability caused by heavy exercise in athletes. <i>American Journal of Physiology - Renal Physiology</i> , 2011 , 300, G477-84	5.1	90
114	Pancreatic secretory trypsin inhibitor is a major motogenic and protective factor in human breast milk. <i>American Journal of Physiology - Renal Physiology</i> , 2009 , 296, G697-703	5.1	22
113	Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. <i>BJU International</i> , 2009 , 103, 1256-69	5.6	52
112	Intestinal protective effect of a commercial fish protein hydrolysate preparation. <i>Regulatory Peptides</i> , 2009 , 155, 105-9		22
111	Newly identified genetic risk variants for celiac disease related to the immune response. <i>Nature Genetics</i> , 2008 , 40, 395-402	36.3	524
110	Clinical trial: protective effect of a commercial fish protein hydrolysate against indomethacin (NSAID)-induced small intestinal injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 799-804	6.1	36
109	What is the role of growth factors in IBD?. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, S119-S120	4.5	
108	Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cellspotential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation. <i>American Journal of Clinical Nutrition</i> , 2008 , 87, 939-48	7	85
107	What is the role of growth factors in IBD?. <i>Inflammatory Bowel Diseases</i> , 2008 , 14 Suppl 2, S119-20	4.5	2
106	NOD2 activity modulates the phenotype of LPS-stimulated dendritic cells to promote the development of T-helper type 2-like lymphocytes - Possible implications for NOD2-associated Crohn's disease. <i>Journal of Crohns and Colitis</i> , 2007 , 1, 106-15	1.5	14
105	A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. <i>Nature Genetics</i> , 2007 , 39, 827-9	36.3	518
104	Dietary microparticles implicated in Crohn's disease can impair macrophage phagocytic activity and act as adjuvants in the presence of bacterial stimuli. <i>Inflammation Research</i> , 2007 , 56, 353-61	7.2	33
103	Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. <i>Gut</i> , 2007 , 56, 168-75	19.2	72
102	Human pancreatic secretory trypsin inhibitor stabilizes intestinal mucosa against noxious agents. <i>American Journal of Pathology</i> , 2007 , 171, 1462-73	5.8	11
101	Modulation of dendritic cell phenotype and function in an in vitro model of the intestinal epithelium. <i>European Journal of Immunology</i> , 2006 , 36, 864-74	6.1	67

100	Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease. <i>European Journal of Immunology</i> , 2006 , 36, 1629-35	6.1	12
99	Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease?. <i>Gut</i> , 2006 , 55, 6-8	19.2	14
98	Lack of association of MYO9B genetic variants with coeliac disease in a British cohort. <i>Gut</i> , 2006 , 55, 969	917522	49
97	Bone marrow-derived stromal cells express lineage-related messenger RNA species. <i>Cancer Research</i> , 2006 , 66, 1265-9	10.1	48
96	Gastroprotective effects of oral nucleotide administration. <i>Gut</i> , 2006 , 55, 165-71	19.2	17
95	New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. <i>Gut</i> , 2006 , 55, 442	19.2	183
94	Interfering with interferons in inflammatory bowel disease. <i>Gut</i> , 2006 , 55, 1071-3	19.2	21
93	Effects of mouse and human lipocalin homologues 24p3/lcn2 and neutrophil gelatinase-associated lipocalin on gastrointestinal mucosal integrity and repair. <i>Gastroenterology</i> , 2006 , 131, 809-17	13.3	68
92	Genetic variation in myosin IXB is associated with ulcerative colitis. <i>Gastroenterology</i> , 2006 , 131, 1768-7	413.3	82
91	Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. <i>Clinical Science</i> , 2006 , 110, 563-73	6.5	17
90	Detection of muramyl dipeptide-sensing pathway defects in patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 598-605	4.5	19
89	Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. <i>Stem Cells</i> , 2006 , 24, 1822-30	5.8	236
88	Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. <i>Lancet, The,</i> 2005 , 365, 1794-6	40	264
87	Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 21, 135	7 ⁶ 6 ¹ 4	41
86	A common CTLA4 haplotype associated with coeliac disease. <i>European Journal of Human Genetics</i> , 2005 , 13, 440-4	5.3	65
85	Synergistic enhancement of Toll-like receptor responses by NOD1 activation. <i>European Journal of Immunology</i> , 2005 , 35, 2471-6	6.1	127
84	Accelerated exposure of phosphatidylserine on lymphocyte populations from patients with systemic lupus erythematosus or rheumatoid arthritis. <i>Thrombosis and Haemostasis</i> , 2005 , 93, 989-992	7	1
83	Intestinal growth in parenterally-fed rats induced by the combined effects of glucagon-like peptide 2 and epidermal growth factor. <i>Journal of Parenteral and Enteral Nutrition</i> , 2005 , 29, 248-54	4.2	26

(2002-2005)

82	Reparative properties of a commercial fish protein hydrolysate preparation. <i>Gut</i> , 2005 , 54, 775-81	19.2	61
81	The value of surveillance and other unresolved issues in the management of Barrett's esophagus. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005 , 2, 60-1		4
80	Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. <i>Gut</i> , 2005 , 54, 1553-7	19.2	92
79	Relevance of Growth Factors for the Gastrointestinal Tract and Other Organs. <i>Nutraceutical Science and Technology</i> , 2005 , 217-241		
78	Probiotics in inflammatory bowel disease: is it all gut flora modulation?. <i>Gut</i> , 2004 , 53, 620-2	19.2	70
77	Effects of growth factors and receptor blockade on gastrointestinal cancer. <i>Gut</i> , 2004 , 53, 1059-63	19.2	2
76	Growth factors and trefoil peptides in gastrointestinal health and disease. <i>Current Opinion in Pharmacology</i> , 2004 , 4, 567-71	5.1	17
75	Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis. <i>Peptides</i> , 2004 , 25, 793-801	3.8	43
74	Development of a two-site ELISA assay for the dimeric form of human TFF1. <i>Peptides</i> , 2004 , 25, 731-6	3.8	4
73	Growth Factors 2004 , 249-256		
73 7 ²	Growth Factors 2004 , 249-256 Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. <i>New England Journal of Medicine</i> , 2003 , 349, 350-7	59.2	246
	Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative	59.2 6.5	246 57
72	Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. <i>New England Journal of Medicine</i> , 2003 , 349, 350-7 Bioactive natural compounds for the treatment of gastrointestinal disorders. <i>Clinical Science</i> , 2003 ,		·
7 ²	Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. <i>New England Journal of Medicine</i> , 2003 , 349, 350-7 Bioactive natural compounds for the treatment of gastrointestinal disorders. <i>Clinical Science</i> , 2003 , 104, 547-56 Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK.	6.5	57
7 ² 7 ¹ 7 ⁰	Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. <i>New England Journal of Medicine</i> , 2003 , 349, 350-7 Bioactive natural compounds for the treatment of gastrointestinal disorders. <i>Clinical Science</i> , 2003 , 104, 547-56 Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17, 1319-24 Surveillance for Barrett's oesophagus: is there light the end of the metaplastic tunnel?. <i>Journal of</i>	6.5	57
7 ² 7 ¹ 7 ⁰ 69	Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. New England Journal of Medicine, 2003, 349, 350-7 Bioactive natural compounds for the treatment of gastrointestinal disorders. Clinical Science, 2003, 104, 547-56 Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK. Alimentary Pharmacology and Therapeutics, 2003, 17, 1319-24 Surveillance for Barrett's oesophagus: is there light the end of the metaplastic tunnel?. Journal of the Royal College of Surgeons of Edinburgh, 2003, 1, 152-6	6.5	57 51 1
72 71 70 69 68	Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. <i>New England Journal of Medicine</i> , 2003 , 349, 350-7 Bioactive natural compounds for the treatment of gastrointestinal disorders. <i>Clinical Science</i> , 2003 , 104, 547-56 Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17, 1319-24 Surveillance for Barrett's oesophagus: is there light the end of the metaplastic tunnel?. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2003 , 1, 152-6 GERD 2003 — a consensus on the way ahead. <i>Digestion</i> , 2003 , 67, 111-7 Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial	6.5 6.1 2.5 3.6	57 51 1 32

64	Cost analysis of breath test versus endoscopy for dyspepsia. <i>Digestion</i> , 2002 , 65, 207-12	3.6	6
63	Antagonist: endoscopic surveillance of patients with Barrett's oesophagus. <i>Gut</i> , 2002 , 51, 314-5	19.2	12
62	Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage. <i>American Journal of Pathology</i> , 2002 , 161, 373-9	5.8	68
61	Nitric oxide regulates the release of somatostatin from cultured gastric rabbit primary D-cells. <i>Gastroenterology</i> , 2002 , 123, 566-76	13.3	15
60	Does Helicobacter pylori eradication reduce the long-term requirements for acid suppressants in patients with a history of peptic ulcer disease in general practice? Results from a four-year longitudinal study. <i>Scandinavian Journal of Gastroenterology</i> , 2002 , 37, 144-7	2.4	7
59	Once you start, you can't stop. Lancet, The, 2002 , 359, 226	40	2
58	Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability. <i>Clinical Science</i> , 2001 , 100, 627-633	6.5	63
57	Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability. <i>Clinical Science</i> , 2001 , 100, 627	6.5	41
56	Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. <i>Gut</i> , 2001 , 48, 803-7	19.2	52
55	Epidermal growth factor reduces multiorgan failure induced by thioacetamide. <i>Gut</i> , 2001 , 48, 34-40	19.2	37
54	Landscaper seeks remunerative position. <i>Gut</i> , 2001 , 48, 594-5	19.2	4
53	Effect of ectopic expression of rat trefoil factor family 3 (intestinal trefoil factor) in the jejunum of transgenic mice. <i>Journal of Biological Chemistry</i> , 2001 , 276, 24088-96	5.4	40
52	Liver biopsy: Blindlbr under ultrasound control. <i>Gut</i> , 2001 , 49, 157-158	19.2	78
51	Epidermal growth factor enemas are effective in the treatment of left-sided ulcarative colitis. <i>Gastroenterology</i> , 2001 , 120, A11-A12	13.3	4
50	Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. <i>American Journal of Clinical Nutrition</i> , 2000 , 72, 5-14	7	254
49	Peptide gene expression in gastrointestinal mucosal ulceration: ordered sequence or redundancy?. <i>Gut</i> , 2000 , 46, 286-92	19.2	54
48	Potency and stability of C terminal truncated human epidermal growth factor. <i>Gut</i> , 2000 , 47, 622-7	19.2	26
47	Does the response of the intestinal epithelium to keratinocyte growth factor vary according to the method of administration?. <i>Regulatory Peptides</i> , 2000 , 87, 83-90		12

46	Reprogramming of intestinal differentiation and intercalary regeneration in Cdx2 mutant mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 7318-23	11.5	242
45	Bovine colostrum is a health food supplement which prevents NSAID induced gut damage. <i>Gut</i> , 1999 , 44, 653-8	19.2	112
44	Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 2316-21	11.5	99
43	Liver biopsy under ultrasound control: implications for training in the Calman era. <i>Gut</i> , 1999 , 45, 628-9	19.2	7
42	The mucous neck cell in the human gastric corpus: a distinctive, functional cell lineage. <i>Journal of Pathology</i> , 1999 , 187, 331-7	9.4	42
41	The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. <i>Journal of Pathology</i> , 1999 , 188, 312-7	9.4	58
40	The Trefoil Peptide TFF1 Inhibits the Growth of the Human Gastric Adenocarcinoma Cell Line, AGS. <i>Clinical Science</i> , 1999 , 96, 1P-1P		
39	Pantoprazole, Prout and the proton pump. British Journal of Hospital Medicine, 1999, 60, 500-4		5
38	Effects of keratinocyte growth factor (KGF) on gut growth and repair. <i>Journal of Pathology</i> , 1998 , 184, 316-22	9.4	37
37	Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects. <i>Journal of Pathology</i> , 1998 , 185, 153-8	9.4	63
36	Expression of catenins and E-cadherin during epithelial restitution in inflammatory bowel disease. Journal of Pathology, 1998 , 185, 413-8	9.4	103
35	Human pancreatic secretory trypsin inhibitor. Distribution, actions and possible role in mucosal integrity and repair. <i>Digestion</i> , 1998 , 59, 167-74	3.6	48
34	Growth factors and gut function. <i>Proceedings of the Nutrition Society</i> , 1998 , 57, 403-8	2.9	8
33	Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects 1998 , 185, 153		1
32	Ten years' experience of screening patients with Barrett's oesophagus in a university teaching hospital. <i>Gut</i> , 1997 , 41, 303-7	19.2	42
31	Growth factors in saliva. <i>Lancet, The</i> , 1997 , 350, 369	40	1
30	Effects of a panel of dietary lectins on cholecystokinin release in rats. <i>American Journal of Physiology - Renal Physiology</i> , 1997 , 273, G946-50	5.1	5
29	Peptide YY and neuropeptide Y: two peptides intimately involved in electrolyte homeostasis. Trends in Pharmacological Sciences, 1996 , 17, 436-8	13.2	36

28	Comparison of the effects of transforming growth factor alpha and epidermal growth factor on gastrointestinal proliferation and hormone release. <i>Digestion</i> , 1996 , 57, 362-7	3.6	28
27	Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 2137-42	11.5	158
26	Growth factors and ulcerative gastrointestinal disease. <i>Baillierers Clinical Gastroenterology</i> , 1996 , 10, 135-49		3
25	The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract. <i>Gut</i> , 1996 , 39, 262-6	19.2	120
24	Cytokines and Helicobacter pyloria growth area. <i>Gut</i> , 1996 , 39, 881-2	19.2	3
23	Why is epidermal growth factor present in the gut lumen?. <i>Gut</i> , 1996 , 38, 303-5	19.2	76
22	Peptides and gastrointestinal mucosal integrity. <i>Gut</i> , 1995 , 37, 595-7	19.2	78
21	Epidermal growth factor is digested to smaller, less active forms in acidic gastric juice. Gastroenterology, 1995 , 108, 92-101	13.3	101
20	Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. <i>Gastroenterology</i> , 1995 , 108, 108-16	13.3	244
19	Epidermal growth factor and intestinal growth. <i>Gastroenterology</i> , 1995 , 108, 1330-1	13.3	2
18	Is glutamine required for the trophic effect of epidermal growth factor?. Surgery, 1995, 117, 355	3.6	
17	Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat. <i>Clinical Science</i> , 1995 , 88, 401-3	6.5	94
16	Luminal epidermal growth factor is trophic to the small intestine of parenterally fed rats. <i>Clinical Science</i> , 1995 , 89, 117-20	6.5	33
15	Influence of inflammation and atrophy on pancreatic secretory trypsin inhibitor levels within the gastric mucosa. <i>Gastroenterology</i> , 1994 , 106, 735-41	13.3	17
14	Effect of luminal growth factor preservation on intestinal growth. <i>Lancet, The</i> , 1993 , 341, 843-8	40	100
13	Effects of diet and the cholecystokinin antagonist; devazepide (L364,718) on CCK mRNA, and tissue and plasma CCK concentrations. <i>European Journal of Clinical Investigation</i> , 1993 , 23, 641-7	4.6	4
12	Suppression of Helicobacter pylori reduces gastrin releasing peptide stimulated gastrin release in duodenal ulcer patients. <i>Gut</i> , 1992 , 33, 601-3	19.2	45
11	Whipple's disease complicated by a retinal Jarisch-Herxheimer reaction: a case report. <i>Gut</i> , 1992 , 33, 132-4	19.2	20

LIST OF PUBLICATIONS

10	pH-dependent secretion of gastrin in duodenal ulcer disease: effect of suppressing Helicobacter pylori. <i>Digestion</i> , 1992 , 52, 173-8	8
9	Effect of chymotrypsin on human cholecystokinin release: use of clostripain in the validation of a new radioimmunoassay. <i>Regulatory Peptides</i> , 1992 , 40, 1-12	19
8	Dose-dependent effects of fentanyl on indomethacin-induced gastric damage. <i>Digestion</i> , 1991 , 49, 198-208	18
7	Gastric output of pancreatic secretory trypsin inhibitor is increased by misoprostol. <i>Gut</i> , 1991 , 32, 1396-4@02	23
6	Hypergastrinaemia: a new mechanism. <i>Lancet, The</i> , 1991 , 338, 410-1	9
5	Pancreatic secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice. <i>Gut</i> , 1990 , 31, 1318-23 _{19.2}	35
4	Bismuth induced encephalopathy caused by tri potassium dicitrato bismuthate in a patient with chronic renal failure. <i>Gut</i> , 1990 , 31, 359-60	45
3	Preliminary report: role of peptide YY in defence against diarrhoea. <i>Lancet, The</i> , 1990 , 335, 1555-7 40	59
2	Right ventricular pacing wire thrombus presenting as pyrexia of unknown origin. <i>Clinical Cardiology</i> , 1989 , 12, 106-8	8
1	Campylobacter pylori and duodenal ulcers: the gastrin link. <i>Lancet, The</i> , 1989 , 1, 1167-8	314